MANNKIND CORP (MNKD) Stock Overview
NASDAQ:MNKD - US56400P7069 - Common Stock
MNKD Key Statistics, Chart & Performance
The current stock price of MNKD is 4.49 USD. In the past month the price increased by 18.78%. In the past year, price decreased by -28.27%.
MNKD Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 19.63 | 367.30B | ||
| AMGN | AMGEN INC | 13.1 | 153.76B | ||
| GILD | GILEAD SCIENCES INC | 14.54 | 139.67B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 23.14 | 100.52B | ||
| REGN | REGENERON PHARMACEUTICALS | 12.7 | 61.43B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 59.29B | ||
| ARGX | ARGENX SE - ADR | 75.95 | 43.09B | ||
| ONC | BEONE MEDICINES LTD-ADR | 6.02 | 35.42B | ||
| INSM | INSMED INC | N/A | 28.53B | ||
| BNTX | BIONTECH SE-ADR | N/A | 24.50B | ||
| NTRA | NATERA INC | N/A | 23.04B | ||
| BIIB | BIOGEN INC | 8.29 | 19.45B |
Related stock screener links
About MNKD
Company Profile
MannKind Corp. is a biopharmaceutical company, which focuses on the development and commercialization of innovative therapeutic products and devices to address serious unmet medical needs for those living with endocrine and orphan lung diseases. The company is headquartered in Danbury, Connecticut and currently employs 407 full-time employees. The company went IPO on 2004-07-28. The firm's technologies include Technosphere dry-powder formulations and Dreamboat inhalation devices. In its endocrine business unit, it commercializes two products: Afrezza (insulin human) Inhalation Powder, an ultra rapid-acting inhaled insulin indicated to improve glycemic control in adults with diabetes, and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults that require insulin. Its orphan lung disease product, Tyvaso DPI (treprostinil) inhalation powder, is used in the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). Its pipeline products include Pediatric Afrezza (insulin human) Inhalation Powder, MNKD-101 and MNKD-201.
Company Info
MANNKIND CORP
1 Casper Street
Danbury CONNECTICUT 91362 US
CEO: Michael E. Castagna
Employees: 405
Phone: 18186615000
MANNKIND CORP / MNKD FAQ
What is the stock price of MANNKIND CORP today?
The current stock price of MNKD is 4.49 USD. The price decreased by -0.66% in the last trading session.
What is the ticker symbol for MANNKIND CORP stock?
The exchange symbol of MANNKIND CORP is MNKD and it is listed on the Nasdaq exchange.
On which exchange is MNKD stock listed?
MNKD stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for MANNKIND CORP stock?
14 analysts have analysed MNKD and the average price target is 9.44 USD. This implies a price increase of 110.13% is expected in the next year compared to the current price of 4.49. Check the MANNKIND CORP stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is MANNKIND CORP worth?
MANNKIND CORP (MNKD) has a market capitalization of 1.38B USD. This makes MNKD a Small Cap stock.
How many employees does MANNKIND CORP have?
MANNKIND CORP (MNKD) currently has 405 employees.
What are the support and resistance levels for MANNKIND CORP (MNKD) stock?
MANNKIND CORP (MNKD) has a support level at 3.89 and a resistance level at 4.5. Check the full technical report for a detailed analysis of MNKD support and resistance levels.
Is MANNKIND CORP (MNKD) expected to grow?
The Revenue of MANNKIND CORP (MNKD) is expected to grow by 13.93% in the next year. Check the estimates tab for more information on the MNKD EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy MANNKIND CORP (MNKD) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of MNKD, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of MNKD, evaluating the profitability, health, valuation and growth aspects
- MANNKIND CORP (MNKD) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- MANNKIND CORP (MNKD) Sales and EPS estimates to see what analysts future expectations are.
- MANNKIND CORP (MNKD) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- MANNKIND CORP (MNKD) Insider and Institutional Ownership to learn about the owners and their transactions.
- MANNKIND CORP (MNKD) Stock Chart to make your own analysis
- MANNKIND CORP (MNKD) Latest news and press-releases to stay up to date.
Does MANNKIND CORP (MNKD) stock pay dividends?
MNKD does not pay a dividend.
When does MANNKIND CORP (MNKD) report earnings?
MANNKIND CORP (MNKD) will report earnings on 2025-11-05, after the market close.
What is the Price/Earnings (PE) ratio of MANNKIND CORP (MNKD)?
The PE ratio for MANNKIND CORP (MNKD) is 49.89. This is based on the reported non-GAAP earnings per share of 0.09 and the current share price of 4.49 USD. Check the full fundamental report for a full analysis of the valuation metrics for MNKD.
What is the Short Interest ratio of MANNKIND CORP (MNKD) stock?
The outstanding short interest for MANNKIND CORP (MNKD) is 7.88% of its float. Check the ownership tab for more information on the MNKD short interest.
MNKD Technical Analysis
ChartMill assigns a technical rating of 5 / 10 to MNKD. When comparing the yearly performance of all stocks, MNKD is a bad performer in the overall market: 83.89% of all stocks are doing better.
MNKD Fundamental Analysis
ChartMill assigns a fundamental rating of 5 / 10 to MNKD. MNKD has only an average score on both its financial health and profitability.
MNKD Financial Highlights
Over the last trailing twelve months MNKD reported a non-GAAP Earnings per Share(EPS) of 0.09. The EPS increased by 125% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 10.71% | ||
| ROA | 7.85% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
MNKD Forecast & Estimates
14 analysts have analysed MNKD and the average price target is 9.44 USD. This implies a price increase of 110.13% is expected in the next year compared to the current price of 4.49.
For the next year, analysts expect an EPS growth of 69.4% and a revenue growth 13.93% for MNKD